Medicxi

Curevo is a clinical-stage biotechnology company developing next-generation, non-mRNA vaccines to address unmet medical needs. Its lead candidate, amezosvatein (also known as CRV-101), is an adjuvanted subunit vaccine designed to prevent shingles (herpes zoster) and chickenpox (varicella). The company focuses on improving vaccine efficacy, safety, and tolerability while advancing its pipeline through clinical trials.

RAPT Therapeutics is a clinical-stage biopharmaceutical company specializing in immunology. It focuses on discovering, developing, and commercializing oral small-molecule therapies aimed at addressing significant unmet medical needs in oncology and inflammatory diseases. RAPT's proprietary discovery engine has led to the advancement of two drug candidates: FLX475, which selectively inhibits the migration of immunosuppressive regulatory T cells into tumors, and RPT193, which targets type 2 T helper cells in inflamed tissues. Both candidates have progressed to clinical trials within a short time frame since the company's inception. Additionally, RAPT is exploring further therapeutic targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1, which are currently in the discovery phase.

Ottimo Pharma focuses on creating pioneering cancer treatments for solid tumors, specifically through its lead program, Jankistomig, a bi-functional antibody targeting immune checkpoints and angiogenesis. The company aims to enhance treatment outcomes and alleviate healthcare burdens by advancing this dual-pathway approach.

Ottimo Pharma focuses on creating pioneering cancer treatments for solid tumors, specifically through its lead program, Jankistomig, a bi-functional antibody targeting immune checkpoints and angiogenesis. The company aims to enhance treatment outcomes and alleviate healthcare burdens by advancing this dual-pathway approach.

ViceBio is a biopharmaceutical company focused on developing innovative vaccines to combat respiratory viral infectious diseases. Utilizing its patented Molecular Clamp Technology, ViceBio stabilizes viral glycoproteins in their prefusion conformation, which allows for the creation of effective and ready-to-use liquid vaccines. This technology enables long-term storage and easy administration of vaccines targeting various respiratory viruses, including respiratory syncytial virus (RSV), metapneumovirus, influenza, and SARS-CoV-2. Through its commitment to advancing vaccination strategies, ViceBio aims to prevent potentially fatal infections caused by these viruses.

D3 Bio is a biotechnology company dedicated to the discovery, development, and registration of innovative medicines in oncology and immunology. The company aims to address existing gaps in conventional treatments by utilizing clinical and market data to identify areas for improvement. D3 Bio employs unique drug development methodologies that target new diseases and delivery methods, ultimately providing patients with alternative therapeutic options in these critical areas of healthcare.

ProfoundBio is a clinical-stage biotechnology company dedicated to creating innovative antibody-based therapeutics aimed at treating cancer. Utilizing proprietary technology platforms, the company has developed a diverse pipeline of antibody-drug conjugate (ADC) candidates targeting both solid tumors and hematological malignancies. These drug candidates are currently in various stages of discovery, preclinical, and clinical development. ProfoundBio's focus is on harnessing the immune system to provide patients with more effective treatments that have the potential for curative outcomes.

Alys Pharmaceuticals is a company dedicated to advancing immuno-dermatology services through innovative scientific research and development. By strategically aggregating six asset-centric companies, Alys aims to transform treatment paradigms for various dermatological conditions. Its multi-platform pipeline is designed to optimize the impact of its diverse asset classes, enabling the healthcare industry to access transformative solutions for a wide range of dermatological indications. Through a strong focus on research and development, Alys Pharmaceuticals is reshaping the treatment landscape in the field of dermatology.

Fore Biotherapeutics is a clinical-stage biotechnology company focused on developing precision oncology treatments tailored to patients with specific genetic mutations. By utilizing functional genomics, the company aims to create a pipeline of therapies that address unmet needs in cancer care. Fore Biotherapeutics conducts research to replicate naturally occurring mutations in vitro, allowing for the assessment of their impact on cellular signaling pathways and responses to various compounds. This approach not only facilitates the identification of novel target mutations but also helps biopharma companies broaden the patient subgroups that may benefit from existing cancer therapies.

Aldena Therapeutics is a private biotechnology startup focused on developing innovative treatments for dermatological conditions using siRNA-based therapies. The company specializes in microneedle technology that delivers medicinal skin creams containing microscopic STAR particles, which are designed to facilitate the administration of nucleic acid therapies. This approach aims to address various skin conditions that pose significant challenges for patients, offering a novel solution with the potential for improved therapeutic outcomes.

NewAmsterdam Pharma is a clinical-stage biopharmaceutical company dedicated to the research and development of innovative therapies for cardio-metabolic diseases. The company aims to enhance patient care for those suffering from metabolic conditions where existing treatments are insufficient or poorly tolerated. Its lead product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor designed to address the shortcomings of current LDL-C lowering therapies. Through its focus on transformative solutions, NewAmsterdam Pharma seeks to make a significant impact in the management of cardio-metabolic diseases.

Rivus Pharmaceuticals is a biopharmaceutical company focused on enhancing cardio-metabolic health through the development of controlled metabolic accelerators (CMAs). These innovative therapeutics aim to improve cellular metabolism and target the root causes of prevalent metabolic and cardiovascular diseases. By providing oral small-molecule treatments, Rivus addresses critical metabolic risk factors associated with cardiovascular mortality and morbidity, thereby contributing to better health outcomes for patients suffering from these conditions.

MiroBio Ltd is a biotechnology company based in Oxford, United Kingdom, focused on developing antibody modulators for immune cell receptors aimed at treating autoimmune diseases. Founded in 2018, MiroBio leverages pioneering research from the University of Oxford to understand how immune cells communicate and are activated. This foundational knowledge allows the company to create innovative antibodies that stimulate specific immune cell signals, harnessing the body's natural control mechanisms to restore balance within the immune system. By activating these natural pathways, MiroBio's therapeutics aim to provide significant benefits to patients suffering from various autoimmune conditions, enabling clinicians to effectively manage overactive immune responses associated with these diseases.

Xenikos is focused on developing innovative immunotherapy treatments aimed at addressing serious immune diseases and complications arising from transplants. The company specializes in anti-T-cell antibodies that can effectively reset the immune system. This therapeutic approach involves injecting a specific agent that targets and eliminates adult T cells, particularly those that are activated, thereby enhancing treatment outcomes for patients. By leveraging this unique mechanism, Xenikos seeks to restore health and improve the quality of life for individuals facing significant immune-related challenges.

Versanis Bio is focused on discovering and developing medicines that target medical conditions commonly found in older adults. The company is advancing Bimagrumab, a human monoclonal antibody that inhibits activin type II receptors, blocking the action of ligands such as activin A and myostatin. Previous studies conducted by Novartis involved over 1,500 participants and demonstrated that Bimagrumab consistently induced significant fat loss while preserving lean mass. Additionally, the treatment has shown improvements in HbA1c levels and other cardiometabolic parameters, offering a promising option for overweight and obese adults aiming to achieve and maintain a healthier body composition.

Sydnexis is focused on developing a proprietary treatment for pediatric progressive myopia, addressing a significant global medical need. The company manufactures a topical eyedrop formulation specifically designed to treat the progression of myopia in children. This innovative approach enables healthcare professionals to effectively manage and reduce the incidence of eye disorders in pediatric patients.

Rivus Pharmaceuticals is a biopharmaceutical company focused on enhancing cardio-metabolic health through the development of controlled metabolic accelerators (CMAs). These innovative therapeutics aim to improve cellular metabolism and target the root causes of prevalent metabolic and cardiovascular diseases. By providing oral small-molecule treatments, Rivus addresses critical metabolic risk factors associated with cardiovascular mortality and morbidity, thereby contributing to better health outcomes for patients suffering from these conditions.

Kurome Therapeutics, Inc. is a preclinical stage company based in Cincinnati, Ohio, focused on developing innovative therapies to combat cancer. The company targets cancer cells that have hijacked immune signaling pathways, allowing them to evade traditional treatments and develop resistance. By creating inhibitors that disrupt these dysregulated immune signaling mechanisms, Kurome Therapeutics aims to enhance the effectiveness of cancer therapies, particularly for hematological cancers. Founded in 2019, the company is dedicated to addressing the challenges of cancer treatment by providing new options that aim to overcome the survival tactics employed by cancer cells.

Aura Biosciences, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing therapies to target and destroy cancer cells using viral nanoparticle conjugates. The company’s lead product, AU-011, utilizes viral nanoparticles modeled on the human papillomavirus, conjugated with infrared-activated small molecules, specifically for the treatment of ocular melanoma, a primary eye cancer. By employing nanotechnology, Aura aims to safely eliminate cancer locally, particularly in early-stage cases, to prevent progression to more severe forms of the disease, such as metastasis to the liver. Additionally, the company is advancing its bel-sar candidate for treating primary choroidal melanoma and exploring applications in bladder cancer. Founded in 2007, Aura Biosciences is committed to developing precision immunotherapies that preserve the function of organs affected by cancer.

SynOx Therapeutics is a clinical-stage biopharmaceutical company based in Dublin, Ireland, that specializes in the development of innovative therapies for cancer. The company's primary focus is on emactuzumab, a humanized monoclonal antibody targeting CSF-1R, aimed at depleting macrophages within tumor tissues. This therapy is being investigated for its potential in treating diffuse tenosynovial giant cell tumors and other macrophage-mediated diseases. Established in 2019, SynOx Therapeutics is backed by experienced investors in the biopharmaceutical field, emphasizing its commitment to addressing the unmet clinical needs of patients and improving their quality of life through advanced treatment options.

Janpix Ltd. is a biopharmaceutical company focused on the development of innovative cancer treatments through the discovery of inhibitors targeting Signal Transducer and Activator of Transcription (STAT) proteins. Founded in 2017 and based in Cambridge, Massachusetts, with a research facility in Mississauga, Canada, Janpix aims to address the challenges associated with inhibiting STAT proteins, particularly STAT3 and STAT5, which are linked to various cancers. The company has developed ultra-selective STAT inhibitors that not only target hematological tumors and glioblastomas but also modulate immune cells and the tumor microenvironment to enhance cancer eradication. Janpix's research is driven by the goal of providing effective treatment options for patients facing these complex diseases.

Palladio Biosciences, Inc. is a biotechnology company focused on developing transformative medicines for orphan diseases of the kidney. Founded in 2015 and based in Horsham, Pennsylvania, the company is in the clinical stage and specializes in therapeutics aimed at renal diseases, particularly polycystic kidney disease (PKD). One of its key developments is Lixivaptan, a selective vasopressin V2 receptor antagonist designed to treat PKD, a life-threatening genetic disorder characterized by the growth of numerous fluid-filled cysts in the kidneys. Palladio Biosciences aims to provide innovative treatment options that can help prevent the progression of kidney diseases.

Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing novel immunotherapies for cancer treatment. The company specializes in CpG oligonucleotides, which are designed to stimulate an anti-tumor T-cell response while counteracting the mechanisms that tumors use to evade the immune response. Checkmate aims to enhance the effectiveness of existing immunotherapies and provide new treatment options for patients through its innovative approaches. Since its incorporation in 2015, Checkmate has established strategic partnerships with major pharmaceutical companies, including Merck KGaA and Pfizer, to advance its clinical programs and broaden the impact of its research in the field of cancer immunotherapy.

Vaxcyte, Inc. is a biotechnology company focused on developing innovative vaccines to prevent and treat infectious diseases globally. The company’s lead candidate, VAX-24, is a 24-valent investigational pneumococcal conjugate vaccine. Additionally, Vaxcyte is advancing VAX-XP, which targets emerging strains that contribute to invasive pneumococcal disease and antibiotic resistance. Other notable candidates include VAX-A1, designed to protect against Group A Streptococcus infections, and VAX-PG, a therapeutic vaccine aimed at treating periodontal disease caused by Porphyromonas gingivalis. Vaxcyte utilizes a proprietary cell-free protein synthesis platform that enables the creation of protein carriers and antigens, enhancing vaccine development beyond conventional methods. Founded in 2013 and headquartered in Foster City, California, the company was previously known as SutroVax, Inc. before rebranding in May 2020.

Alderaan Biotechnology is a biotechnology company focused on developing innovative antibodies for cancer treatment, specifically targeting new and original immuno-oncology targets expressed by Natural Killer (NK) cells. The company specializes in monoclonal antibodies that aim to deplete regulatory T (Treg) cells within the tumor microenvironment, thereby enhancing the cytotoxic activity of NK cells. By creating these targeted therapies, Alderaan Biotechnology seeks to provide physicians with effective tools to improve cancer treatment outcomes through advanced immunotherapy approaches.

Vaderis Therapeutics is a biotechnology company focused on developing oral medications for the treatment of rare and orphan diseases, particularly those associated with vascular malformations. The company's primary product aims to address the symptoms of hereditary hemorrhagic telangiectasia (HHT), a condition characterized by abnormal blood vessel formation. By reducing the occurrence of new lesions, Vaderis Therapeutics' treatment enables healthcare providers to better manage disease progression in patients with HHT. Currently in the clinical stages, the company is dedicated to advancing therapies that target these uncommon conditions.

Divide & Conquer is a biotechnology company based in Cambridge, United Kingdom, founded in 2018. The company specializes in the development and manufacturing of therapeutics aimed at treating glioblastoma, a highly aggressive form of brain cancer, as well as other solid tumors such as breast, pancreatic, prostate, lung, and colorectal cancers. Collaborating with the University of Heidelberg and the German Cancer Research Center, Divide & Conquer is focused on innovative approaches that disrupt cell-to-cell communication within tumors. By targeting malignant cellular networks and related structures, the company aims to enhance treatment efficacy and improve patient outcomes. Funded by the venture capital firm Medicxi, Divide & Conquer is positioned to contribute significantly to the field of oncology through its unique therapeutic strategies.

Breakpoint Therapeutics GmbH, located in Hamburg, Germany, specializes in the discovery and development of innovative anti-cancer drugs. The company focuses on targeting the DNA damage response (DDR) in cancer cells, specifically aiming to disrupt pathways related to DNA repair and replication stress tolerance. By doing so, Breakpoint Therapeutics seeks to advance first-in-class oncology drugs that not only complement existing treatments, such as PARP inhibitors, but also address the challenge of therapy-resistant cancers. Through its research and development efforts, the company aspires to enhance treatment options for patients facing difficult-to-treat cancer types.

Yukin Therapeutics is a French biotechnology company specializing in the development of kinase inhibitors aimed at targeting the NIK protein, which plays a critical role in the progression of various cancers. The company is focused on creating therapeutic molecules that modify the tumor microenvironment, facilitating immune system infiltration to enhance the efficacy of existing cancer immunotherapies. Yukin Therapeutics has successfully conducted studies demonstrating proof of concept in animal models and is now in the process of identifying a first drug candidate for clinical trials in oncology, with the goal of improving treatment options for cancers such as skin and pancreatic cancer.

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Buffalo Grove, Illinois, focused on developing and commercializing innovative treatments for gastrointestinal diseases. Established in 2018 and launched in 2019, the company is advancing its lead drug candidate, vonoprazan, a potassium-competitive acid blocker (P-CAB) that effectively inhibits acid secretion in the stomach. Vonoprazan is currently undergoing Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease and is also being studied in combination with antibiotics for the treatment of Helicobacter pylori infection. The company aims to address significant unmet medical needs in patients suffering from acid-related disorders and has assembled a team of experts in the gastrointestinal and pharmaceutical fields to drive its development efforts.

Aura Biosciences, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing therapies to target and destroy cancer cells using viral nanoparticle conjugates. The company’s lead product, AU-011, utilizes viral nanoparticles modeled on the human papillomavirus, conjugated with infrared-activated small molecules, specifically for the treatment of ocular melanoma, a primary eye cancer. By employing nanotechnology, Aura aims to safely eliminate cancer locally, particularly in early-stage cases, to prevent progression to more severe forms of the disease, such as metastasis to the liver. Additionally, the company is advancing its bel-sar candidate for treating primary choroidal melanoma and exploring applications in bladder cancer. Founded in 2007, Aura Biosciences is committed to developing precision immunotherapies that preserve the function of organs affected by cancer.

Orexia Limited is a biotechnology company based in London, United Kingdom, focused on developing innovative therapies for neurological diseases. Incorporated in 2018, the company specializes in oral orexin positive modulators aimed at treating narcolepsy, a rare neurological condition that disrupts the brain's regulation of the sleep-wake cycle. By targeting the G protein-coupled receptors Orexin OX1 and OX2, Orexia seeks to restore orexin levels in the brain, thereby addressing the symptoms associated with this disorder.

Inexia Limited is a biotechnology company based in London, UK, founded in 2018. The company focuses on developing novel therapies utilizing positive modulators of the G protein-coupled receptors, Orexin OX1 and OX2, to address neurological diseases. Specifically, Inexia is working on intranasally administered orexin positive modulators aimed at treating narcolepsy, a condition linked to the loss of orexin neurons. The intact and functional orexin receptors in patients present a therapeutic opportunity for intervention. By employing a unique exhalation delivery system, Inexia's approach aims to restore orexin levels in the brain, thereby alleviating symptoms associated with narcolepsy and potentially enhancing patients' overall quality of life.

Morphogen-IX Limited is a biotechnology company based in Cambridge, United Kingdom, focused on developing novel treatments for pulmonary arterial hypertension (PAH), a serious condition affecting lung blood vessels that can lead to heart failure. Founded in 2015 by Index Ventures, the company is exploring the therapeutic potential of bone morphogenetic proteins (BMPs), particularly BMP9 and BMP10, which have shown promise in enhancing BMPR-II receptor signaling in endothelial cells. This signaling is crucial for reversing the effects of PAH, as compromised BMPR-II signaling is central to the disease's pathology. Current PAH treatments primarily address symptoms, and effective long-term solutions are limited, often requiring risky lung transplants. Morphogen-IX employs a semi-virtual business model, leveraging a network of experienced professionals in drug discovery while maintaining operational efficiency through outsourcing. The company's founders are recognized experts in both PAH and BMP research, positioning Morphogen-IX to potentially transform the treatment landscape for this life-limiting disease.

Vaxcyte, Inc. is a biotechnology company focused on developing innovative vaccines to prevent and treat infectious diseases globally. The company’s lead candidate, VAX-24, is a 24-valent investigational pneumococcal conjugate vaccine. Additionally, Vaxcyte is advancing VAX-XP, which targets emerging strains that contribute to invasive pneumococcal disease and antibiotic resistance. Other notable candidates include VAX-A1, designed to protect against Group A Streptococcus infections, and VAX-PG, a therapeutic vaccine aimed at treating periodontal disease caused by Porphyromonas gingivalis. Vaxcyte utilizes a proprietary cell-free protein synthesis platform that enables the creation of protein carriers and antigens, enhancing vaccine development beyond conventional methods. Founded in 2013 and headquartered in Foster City, California, the company was previously known as SutroVax, Inc. before rebranding in May 2020.

Xenikos is focused on developing innovative immunotherapy treatments aimed at addressing serious immune diseases and complications arising from transplants. The company specializes in anti-T-cell antibodies that can effectively reset the immune system. This therapeutic approach involves injecting a specific agent that targets and eliminates adult T cells, particularly those that are activated, thereby enhancing treatment outcomes for patients. By leveraging this unique mechanism, Xenikos seeks to restore health and improve the quality of life for individuals facing significant immune-related challenges.

Synthorx, Inc. is a biopharmaceutical company based in La Jolla, California, focused on developing innovative cytokine Synthorin programs for the treatment of cancer and autoimmune disorders. The company's lead product candidate, THOR-707, is a variant of recombinant human IL-2 being explored for various solid tumors, both as a standalone treatment and in combination with immune checkpoint inhibitors. Additionally, Synthorx is working on IL-2 Synthorin for autoimmune conditions, IL-10 Synthorin for immuno-oncology, and IL-15 Synthorins to enhance immune regulation. The company employs advanced synthetic biology techniques, utilizing a novel DNA base pair to create proteins with enhanced specificity, safety, and efficacy. These developments enable the manufacturing of improved therapeutics that can better modulate pharmacological properties compared to traditional biologics. Synthorx, which was established in 2014 and previously known as Alinos, Inc., operates as a subsidiary of Sanofi and holds exclusive rights to its innovative synthetic biology technology derived from research at The Scripps Research Institute.

Critical Pressure is a developer of innovative drugs aimed at treating vascular dysfunction and shock. The company's products offer a new approach to clinical practice by minimizing the risks associated with excess fluid administration and the toxicities linked to traditional catecholamine-based vasoactive agents. This technology provides a potential solution for supportive therapy during critical periods of hemodynamic compromise, enhancing patient care without the adverse effects commonly seen with existing treatments.

Impact Biomedicines, Inc. is a biotechnology company focused on the research, development, and commercialization of innovative treatments for patients with myeloproliferative neoplasms and various cancers. Founded in 2016 and based in San Diego, California, the company is primarily developing fedratinib, a potent and highly selective oral small molecule JAK2 kinase inhibitor. This drug is aimed at treating myelofibrosis and polycythemia vera, with potential applications for acute myeloid leukemia and colorectal cancer. Impact Biomedicines operates as a subsidiary of Bristol-Myers Squibb Company.

Janpix Ltd. is a biopharmaceutical company focused on the development of innovative cancer treatments through the discovery of inhibitors targeting Signal Transducer and Activator of Transcription (STAT) proteins. Founded in 2017 and based in Cambridge, Massachusetts, with a research facility in Mississauga, Canada, Janpix aims to address the challenges associated with inhibiting STAT proteins, particularly STAT3 and STAT5, which are linked to various cancers. The company has developed ultra-selective STAT inhibitors that not only target hematological tumors and glioblastomas but also modulate immune cells and the tumor microenvironment to enhance cancer eradication. Janpix's research is driven by the goal of providing effective treatment options for patients facing these complex diseases.

Sydnexis is focused on developing a proprietary treatment for pediatric progressive myopia, addressing a significant global medical need. The company manufactures a topical eyedrop formulation specifically designed to treat the progression of myopia in children. This innovative approach enables healthcare professionals to effectively manage and reduce the incidence of eye disorders in pediatric patients.

Diasome Pharmaceuticals is a clinical-stage company focused on developing innovative diabetes therapeutics. Based in Conshohocken, Pennsylvania, the company specializes in insulin-based therapies designed to optimize diabetes management for patients with Type 1 and Type 2 diabetes. Its flagship product, the hepatocyte directed vesicle (HDV), is a nanoscale carrier that effectively delivers insulin to the liver, enhancing insulin delivery systems and compatible with all existing insulin types and delivery methods. In addition to HDV, Diasome offers Oral HVD-I, a targeted oral insulin in pill or gel cap form, and both short-acting and long-acting injectable insulins. Founded in 2004, the company aims to improve blood sugar control and overall metabolic health through its proprietary technologies.

Palladio Biosciences, Inc. is a biotechnology company focused on developing transformative medicines for orphan diseases of the kidney. Founded in 2015 and based in Horsham, Pennsylvania, the company is in the clinical stage and specializes in therapeutics aimed at renal diseases, particularly polycystic kidney disease (PKD). One of its key developments is Lixivaptan, a selective vasopressin V2 receptor antagonist designed to treat PKD, a life-threatening genetic disorder characterized by the growth of numerous fluid-filled cysts in the kidneys. Palladio Biosciences aims to provide innovative treatment options that can help prevent the progression of kidney diseases.

Z Factor Limited is a drug discovery company established in 2015, focusing on developing therapeutic agents for alpha-1-antitrypsin deficiency. Founded through a collaboration between Index Ventures and the University of Cambridge, the company aims to design innovative treatments that correct the misfolding of the Z variant of alpha-1-antitrypsin. This condition currently has limited treatment options, primarily relying on lung or liver transplantation and augmentation therapy. Z Factor's mission addresses a significant unmet medical need by working to create effective alternatives for patients suffering from this deficiency.

SuperX is a preclinical biopharmaceutical company based at the Babraham Research Campus, focused on developing novel anticoagulant therapies. The company is engaged in the discovery of antibodies targeting components of the blood coagulation cascade, aiming to create anti-thrombotic drugs that reduce the risk of bleeding. By specifically blocking thrombosis, which is a leading cause of heart attacks and strokes, SuperX seeks to provide healthcare institutions and physicians with effective anticoagulation treatments suitable for chronic use. Through its innovative approach, the company aspires to improve patient outcomes in the management of cardiovascular diseases.

ApcinteX specializes in the development and marketing of a novel anticoagulant protein therapy aimed at treating hemophilia. The company's innovative treatment works by modulating the activity of a critical natural anticoagulant pathway, facilitating normal blood clotting in patients with various forms of hemophilia. This therapy is particularly significant for patients who have developed antibodies to traditional replacement factors. Additionally, it is designed to avoid the formation of anti-clotting antibodies and can be administered through simple subcutaneous injections every two weeks, offering a convenient option for ongoing management of the condition.

Mavalon Therapeutics is a company focused on stopping the progression of Parkinson’s disease. The biotechnology company is developing mGluR3 allosteric modulators for the treatment of Parkinson's disease.

Kymo Therapeutics’s ambition is to move forward Metabrain Research’s proprietary program on kynurenine metabolism (KMO) inhibitors towards clinical proof of concept, before seeking partners to complete development and ensure commercialization.

Gadeta is a research and development company focused on creating immunotherapies for cancer treatment. The company has developed a technology platform utilizing combinatorial T cell receptor exchange (CTE) to optimize gamma delta (γδ) T-cell receptors (TCRs), which exhibit enhanced anti-cancer activity. Gadeta's primary product, T Cells Engineered To Express A Defined Gamma Delta TCR (TEGs), demonstrates significant therapeutic potential against both hematological and solid tumors. By employing high-affinity γδ TCRs on αβ T cells, Gadeta's approach aims to improve the proliferation capacity of these T cells, thereby providing healthcare institutions and cancer patients with innovative solutions to combat advanced malignancies.

Capella BioScience specializes in the discovery and development of monoclonal antibodies (mAbs) aimed at creating therapeutics for oncology, autoimmune diseases, and other medical conditions. The company employs proprietary technologies to innovate in the development and commercialization of mAbs-based medicines. In addition to its independent efforts, Capella collaborates with biotechnology firms and academic institutions to advance its research and expand the reach of its therapeutic solutions.

Stealthyx Therapeutics Ltd. is a biotechnology company that specializes in developing a patented drug-targeting platform designed for precise drug delivery at disease sites. The Stealthyx platform employs a fusion protein technology, which combines a protective shell-like structure with pharmacologically active agents linked through enzyme-sensitive cleavage sites. This innovative approach allows for the targeted release of drugs, such as cytokines, small peptides, and antibody fragments, directly at sites of pathology, thereby enhancing their therapeutic effectiveness while minimizing toxicity. Founded in 2002 and headquartered in Babraham, United Kingdom, Stealthyx Therapeutics aims to improve the pharmacokinetic and pharmacodynamic properties of biological agents, making significant strides in the field of targeted therapy.

Fore Biotherapeutics is a clinical-stage biotechnology company focused on developing precision oncology treatments tailored to patients with specific genetic mutations. By utilizing functional genomics, the company aims to create a pipeline of therapies that address unmet needs in cancer care. Fore Biotherapeutics conducts research to replicate naturally occurring mutations in vitro, allowing for the assessment of their impact on cellular signaling pathways and responses to various compounds. This approach not only facilitates the identification of novel target mutations but also helps biopharma companies broaden the patient subgroups that may benefit from existing cancer therapies.